Get the Stockscreener App
25.51
0.58%
-0.15
XOMA Corp stock is currently priced at $25.51, with a 24-hour trading volume of 6,936.
It has seen a -0.58% decreased in the last 24 hours and a +5.20% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $25.54 pivot point. If it approaches the $25.09 support level, significant changes may occur.
Previous Close:
$25.66
Open:
$25.9
24h Volume:
6,936
Market Cap:
$296.90M
Revenue:
$4.76M
Net Income/Loss:
$-40.83M
P/E Ratio:
-9.4833
EPS:
-2.69
Net Cash Flow:
$-18.16M
1W Performance:
+0.28%
1M Performance:
+5.20%
6M Performance:
+59.74%
1Y Performance:
+19.26%
1D Range:
$25.41
$25.90
52W Range:
$13.48
$27.00
XOMA Corp Stock (XOMA) Company Profile
Name
XOMA Corp
Sector
Industry
Phone
510-204-7200
Address
2200 Powell Street, Suite 310, Emeryville, CA
XOMA Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
XOMA Corp Stock (XOMA) Latest News
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect - GlobeNewswire
GlobeNewswire
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ - Yahoo Finance
Yahoo Finance
XOMA Co. (NASDAQ:XOMAP) Short Interest Down 28.6% in April - Defense World
Defense World
XOMA (NASDAQ:XOMA) Stock Passes Above Two Hundred Day Moving Average of $20.97 - MarketBeat
MarketBeat
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss - Yahoo Finance
Yahoo Finance
Xoma: 2Q Earnings Snapshot - Yahoo News UK
Yahoo News UK
XOMA Corp Stock (XOMA) Financials Data
XOMA Corp (XOMA) Revenue 2024
XOMA reported a revenue (TTM) of $4.76 million for the quarter ending December 31, 2023, a -21.06% decline year-over-year.
XOMA Corp (XOMA) Net Income 2024
XOMA net income (TTM) was -$40.83 million for the quarter ending December 31, 2023, a -138.72% decrease year-over-year.
XOMA Corp (XOMA) Cash Flow 2024
XOMA recorded a free cash flow (TTM) of -$18.16 million for the quarter ending December 31, 2023, a -40.99% decrease year-over-year.
XOMA Corp (XOMA) Earnings per Share 2024
XOMA earnings per share (TTM) was -$4.04 for the quarter ending December 31, 2023, a -105.08% decline year-over-year.
XOMA Corp Stock (XOMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sitko Bradley | Chief Investment Officer |
Oct 02 '23 |
Buy |
14.25 |
1,500 |
21,375 |
5,350 |
| Hughes Owen | Exec Chairman and Interim CEO |
Oct 02 '23 |
Buy |
13.83 |
1,000 |
13,830 |
3,500 |
| Hughes Owen | Exec Chairman and Interim CEO |
Sep 26 '23 |
Buy |
14.43 |
2,499 |
36,061 |
2,500 |
| Hughes Owen | Exec Chairman and Interim CEO |
Sep 25 '23 |
Buy |
14.65 |
1 |
15 |
1 |
| Sitko Bradley | Chief Investment Officer |
May 31 '23 |
Buy |
17.13 |
1,500 |
25,700 |
3,500 |
| Hughes Owen | Interim CEO |
May 24 '23 |
Buy |
23.79 |
1,032 |
24,551 |
2,000 |
| Hughes Owen | Interim CEO |
May 23 '23 |
Buy |
23.46 |
968 |
22,706 |
968 |
| Sitko Bradley | Chief Investment Officer |
May 23 '23 |
Buy |
19.00 |
850 |
16,150 |
3,850 |
About XOMA Corp
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
0.77%
1.20%
Cap:
|
Volume (24h):